Press Releases

New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new standards of patient care in GI health CARLSBAD, Calif. , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Palisade Bio  (Nasdaq: PALI), a clinical stage

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first patient has been screened in its Phase 3 study evaluating

Completion of enrollment for Phase 3 study targeted within 18-24 months In multiple clinical studies, LB1148 has demonstrated statistically significant acceleration in the time to the return of normal GI function, and has the potential to prevent damage to GI tissues and shorten the duration of

In-person presentation on Monday, June 13th at 1:45 PM PT CARLSBAD, Calif. , June 07, 2022 (GLOBE NEWSWIRE) -- Palisade Bio  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam ,

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 Ongoing Phase 2 study of LB1148 for the prevention of post-surgical abdominal adhesions CARLSBAD, Calif. , May 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio  (Nasdaq: PALI), a clinical

CARLSBAD, Calif. , May 10, 2022 (GLOBE NEWSWIRE) -- Palisade Bio  (Nasdaq: PALI), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it had made equity grants to four new employees under its 2021 Inducement Plan.

CARLSBAD, Calif. , May 06, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company” or “Palisade Bio”), a clinical-stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal complications, today announced that it has entered into definitive

NMPA clearance expands global Phase 3 clinical development program; Company recently announced clearance from U.S. Food and Drug Administration to commence Phase 3 study Newsoara to fully fund Phase 3 program in China Under the Co-Development Agreement, commencement of Phase 3 program in China will

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022 CARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Palisade Bio  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal

Live moderated video webcast discussion among members of Management and a renowned Key Opinion Leader on Tuesday, May 3rd at 10:00 AM ET CARLSBAD, Calif. , April 29, 2022 (GLOBE NEWSWIRE) -- Palisade Bio  (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and